Amarin (AMRN +2.3%) gains after Aegis Capital initiated the shares with a Buy this morning and a 12-month price target of $25. Aegis cites the "compelling efficacy" of the company's lead drug candidate, a heart drug derived from fish oil. Aegis notes the drug's ability to not only lower high levels of triglycerides but also LDL levels gives it an advantage over current omega-3 fatty acid- derived drugs currently on the market.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 25, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs